Your browser doesn't support javascript.
loading
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Philip, Mary; Fairchild, Lauren; Sun, Liping; Horste, Ellen L; Camara, Steven; Shakiba, Mojdeh; Scott, Andrew C; Viale, Agnes; Lauer, Peter; Merghoub, Taha; Hellmann, Matthew D; Wolchok, Jedd D; Leslie, Christina S; Schietinger, Andrea.
Afiliação
  • Philip M; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Fairchild L; Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Sun L; Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York 10065, USA.
  • Horste EL; Integrated Genomics Operation, Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Camara S; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Shakiba M; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Scott AC; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Viale A; Weill Cornell Medical College, Cornell University, New York, New York 10065, USA.
  • Lauer P; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Merghoub T; Weill Cornell Medical College, Cornell University, New York, New York 10065, USA.
  • Hellmann MD; Integrated Genomics Operation, Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Wolchok JD; Aduro Biotech, Inc., Berkeley, California 94720, USA.
  • Leslie CS; Weill Cornell Medical College, Cornell University, New York, New York 10065, USA.
  • Schietinger A; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Nature ; 545(7655): 452-456, 2017 05 25.
Article em En | MEDLINE | ID: mdl-28514453
ABSTRACT
Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1hi dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1hi tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Linfócitos T CD8-Positivos / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Linfócitos T CD8-Positivos / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos